BUFFALO, N.Y., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to
the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it has been
added to the Russell 2000® and Russell 3000® Indexes, as part of FTSE Russell’s quarterly additions of companies that recently made
their initial public offerings, effective after market closed on September 15, 2017.
“We are pleased to be included in the Russell 2000 and Russell 3000 indexes following our successful initial public offering on
June 14, 2017,” stated Johnson Lau, Athenex’s Chief Executive Officer. “Our inclusion marks an important step in increasing our
visibility to the investment community while we continue our efforts to develop transformative treatments for cancer patients
globally.”
Russell Investment indexes are widely used by investment managers and institutional investors for index funds and as benchmarks
for both passive and active investment strategies. Russell indexes are part of FTSE Russell, a leading global index provider. For
more information, please visit the “Index IPOs Additions” section of the FTSE Russell website.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the
discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms
including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation
Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites, human
absorption biology and through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s
current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition.
The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able
to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and
efficacy as compared to IV administration of the same cytotoxics. The Src Kinase Inhibition platform refers to novel small molecule
compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of
tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader
range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to
improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and
Clarence, New York, Cranford, New Jersey, Houston, Texas, Chicago, Illinois, Hong Kong, Taipei Taiwan, and multiple locations in
Chongqing, China.
CONTACT:
Nick Riehle
Tel: +1-716-427-2952
